Peer Reviewed
Drug update
Biological therapies for rheumatoid arthritis: TNF inhibitors
Recent articles on:
Rheumatoid arthritis
Rheumatoid arthritis
Abstract
The advent of TNF inhibitors represents a significant advance in treatment options for patients with rheumatoid arthritis who are refractory to traditional DMARD therapy.
Key Points
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder of unknown aetiology. It is the most common form of inflammatory arthritis and affects about 0.5 to 1% of the adult population worldwide. The peak incidence of disease onset occurs in people aged between 20 and 40 years, with women representing three-quarters of all those diagnosed with the condition.
Purchase the PDF version of this article
Already a subscriber? Login here.